Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - tapentadol hydrochloride, quantity: 58.24 mg (equivalent: tapentadol, qty 50 mg) - tablet, film coated - excipient ingredients: purified talc; titanium dioxide; croscarmellose sodium; polyvinyl alcohol; lactose monohydrate; macrogol 3350; microcrystalline cellulose; povidone; magnesium stearate - palexia ir is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

grunenthal pharma ltd - tapentadol - film-coated tablet - 100 milligram(s) - other opioids; tapentadol

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

grunenthal pharma ltd - tapentadol - prolonged-release tablet - 100 milligram(s) - other opioids; tapentadol

Μάλτα - Αγγλικά - Medicines Authority

grunenthal gmbh zieglerstrasse 6, 52078 aachen, germany - tapentadol - film-coated tablet - tapentadol 100 mg - analgesics

Μάλτα - Αγγλικά - Medicines Authority

grunenthal gmbh zieglerstrasse 6, 52078 aachen, germany - tapentadol - prolonged-release tablet - tapentadol 100 mg - analgesics

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - tapentadol hydrochloride (unii: 71204kii53) (tapentadol - unii:h8a007m585) - tapentadol 50 mg

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - tapentadol hydrochloride (unii: 71204kii53) (tapentadol - unii:h8a007m585) - nucynta er (tapentadol) is indicated for the management of: - pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate - neuropathic pain associated with diabetic peripheral neuropathy (dpn) in adults severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. limitations of use - because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations [see warnings and precautions (5.1)] , reserve nucynta er for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. - nucynta er is not indicated as an as-needed (prn) analgesic. nucynta er is contraindicated in patients wi

Μάλτα - Αγγλικά - Medicines Authority

medochemie limited 1-10 constantinoupleos street, 3011 limassol, cyprus - prolonged-release tablet - tapentadol 100 mg - analgesics

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

bryant ranch prepack - tapentadol hydrochloride (unii: 71204kii53) (tapentadol - unii:h8a007m585) - tapentadol 50 mg

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - tapentadol hydrochloride (unii: 71204kii53) (tapentadol - unii:h8a007m585) - nucynta (tapentadol) tablets are indicated for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate in adults. limitations of use because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions (5.1)] , reserve nucynta tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products: - have not been tolerated, or are not expected to be tolerated, - have not provided adequate analgesia, or are not expected to provide adequate analgesia nucynta tablets are contraindicated in patients with: - significant respiratory depression [see warnings and precautions (5.2)] - acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see warnings and precautions (5.5)] - known or suspected gastrointestinal obstruction, including suspected paralytic ileus [see warnings and precautions (5.